The significant EPS beat and extended cash runway into 2028 reduce near-term dilution risk. Key catalysts to watch: XTX501 IND submission (mid-2026), Phase 1 initiation (H2 2026), and potential AbbVie milestones up to $31M through H1 2027. The warrant exercise potential ($36.2M) adds upside optionality. Monitor for any delays in IND filings or clinical starts.
Price Chart
Executive Summary
Xilio Therapeutics reported Q1 2026 results with collaboration revenue of $12.6M (up from $2.9M a year ago) and a net loss of $9.5M ($0.58 per share), beating the consensus EPS estimate of -$0.66. The company highlighted a $6.0M AbbVie milestone achieved in Q2 and extended its cash runway into early 2028, while advancing pipeline programs toward IND filings in mid-2026.
Key Financial Metrics
Key Facts
- Q1 2026 collaboration revenue $12.6M vs $2.9M YoY
- Net loss $9.5M ($0.58/share) vs consensus -$0.66 — 222.7% EPS beat
- Cash and equivalents $150.3M as of March 31, 2026, up from $137.5M at year-end 2025
- Achieved $6.0M development milestone under AbbVie collaboration in Q2 2026
- Cash runway extended into early 2028
- On track for XTX501 IND submission mid-2026 and Phase 1 initiation H2 2026
- Preclinical data for XTX601 (CLDN18.2 TCE) presented at AACR April 2026
- Potential for up to $31.0M in additional near-term milestones from AbbVie through H1 2027
- Up to $36.2M in additional gross proceeds if all Series C warrants exercised in H2 2026
Financial Impact
EPS beat of 222.7% vs consensus; collaboration revenue increased 331% YoY; cash position increased $12.8M from year-end 2025
Risk Factors
- Preclinical/clinical failure risk — XTX501 and TCE programs are early-stage
- Dilution risk from Series C warrant exercises ($36.2M potential gross proceeds)
- Dependence on AbbVie and Gilead collaborations for milestone revenue
- Net loss of $9.5M in Q1 2026 with R&D spending increasing 140% YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292720 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.16 (+1.06%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.16 (−4.20%) |
May 12, 2026 23w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
May 12, 2026 23w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.16 (−3.40%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.16 (−4.75%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.16 (−2.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers